Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 4/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.37 |
| ▸ | VDR | P11473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482719 | 0.91 | NR1H4 (0.48) | NR1H4PTGER4P2RX3P2RX2ALOX5 | |
| SCHEMBL1482647 | 0.90 | NR1H4 (0.48) | NR1H4PTGER4CNR1ALOX5KCNH2 | |
| SCHEMBL1482186 | 0.89 | NR1H4 (0.49) | NR1H4CNR1ALOX5KCNH2VDR | |
| SCHEMBL1482722 | 0.87 | NR1H4 (0.49) | NR1H4PTGER4CRHR1GRIN1GRIN2B | |
| SCHEMBL1482662 | 0.86 | NR1H4 (0.51) | NR1H4CRHR1GRIN1GRIN2BALOX5 | |
| SCHEMBL1482505 | 0.84 | ALOX5 (0.44) | NR1H4CRHR1P2RX3ALOX5 | |
| SCHEMBL1482457 | 0.80 | NR1H4 (0.48) | NR1H4PTGER4ALOX5KCNH2VDR | |
| SCHEMBL1482035 | 0.80 | NR1H4 (0.49) | NR1H4PTGER4ALOX5KCNH2VDR | |
| SCHEMBL1482738 | 0.78 | HTR2C (0.42) | NR1H4CRHR1GRIN2BALOX5 | |
| SCHEMBL1482639 | 0.77 | NR1H4 (0.49) | NR1H4P2RX3P2RX2CNR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | NR1H4 776/4885PTGER4 796/4885CRHR1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.